Holen Sie sich die Stockscreener-App
2.03
1.50%
0.03
Schlusskurs vom Vortag:
$2.00
Offen:
$2.01
24-Stunden-Volumen:
11,109
Relative Volume:
0.06
Marktkapitalisierung:
$18.22M
Einnahmen:
$66.38M
Nettoeinkommen (Verlust:
$-14.18M
KGV:
-0.7231
EPS:
-2.8074
Netto-Cashflow:
$-5.17M
1W Leistung:
-1.46%
1M Leistung:
-14.71%
6M Leistung:
+0.00%
1J Leistung:
+36.24%
1-Tages-Spanne:
$2.01
$2.06
1-Wochen-Bereich:
$1.96
$2.30
52-Wochen-Spanne:
$0.95
$2.82
Aytu Biopharma Inc Stock (AYTU) Company Profile
Firmenname
Aytu Biopharma Inc
Sektor
Telefon
(720) 437-6580
Adresse
7900 E. UNION AVENUE, DENVER
Vergleichen Sie AYTU mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
AYTU
Aytu Biopharma Inc
|
2.03 | 20.38M | 66.38M | -14.18M | -5.17M | -2.8074 |
|
ZTS
Zoetis Inc
|
117.69 | 51.60B | 9.40B | 2.65B | 2.24B | 5.935 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.11 | 44.51B | 29.63B | 260.53M | 5.51B | 0.0788 |
|
HLN
Haleon Plc Adr
|
9.64 | 42.35B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
24.72 | 28.04B | 16.70B | -157.13M | 1.19B | -0.1446 |
|
UTHR
United Therapeutics Corp
|
479.90 | 20.52B | 3.08B | 1.24B | 1.07B | 25.61 |
Aytu Biopharma Inc Stock (AYTU) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-07-01 | Eingeleitet | Lake Street | Buy |
| 2025-06-30 | Eingeleitet | Ascendiant Capital Markets | Buy |
| 2021-03-30 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2020-05-29 | Eingeleitet | H.C. Wainwright | Buy |
Aytu Biopharma Inc Aktie (AYTU) Neueste Nachrichten
Will Aytu BioPharma Inc. (AY20) stock profit from fiscal stimulusJuly 2025 Trade Ideas & AI Enhanced Execution Alerts - newser.com
What risks investors should watch in Aytu BioPharma Inc. stockPortfolio Risk Summary & Reliable Entry Point Trade Alerts - newser.com
Published on: 2025-11-20 01:01:33 - newser.com
Is Aytu BioPharma Inc. stock cheap at current valuation2025 Market Trends & Expert Curated Trade Ideas - newser.com
Pre Market Movers: NUTX, AYTU, NOTV Swing Big - RTTNews
What MACD signals say about Aytu BioPharma Inc.July 2025 Update & Low Drawdown Trading Techniques - newser.com
Why Aytu BioPharma Inc. (AY20) stock is trending on social mediaPortfolio Performance Report & Consistent Profit Focused Trading Strategies - newser.com
Why Aytu BioPharma Inc. stock remains resilientJuly 2025 Outlook & Short-Term Trading Alerts - newser.com
Regression analysis insights on Aytu BioPharma Inc. performance2025 Volatility Report & Fast Exit and Entry Trade Guides - newser.com
Aytu BioPharma : Corporate Presentation November 2025 View Presentation - MarketScreener
How Aytu BioPharma Inc. (AY20) stock moves in volatile trading sessionsDay Trade & Daily Technical Stock Forecast Reports - newser.com
Will Aytu BioPharma Inc. stock attract more institutional investorsWeekly Volume Report & Community Shared Stock Ideas - newser.com
Aytu BioPharma, Inc. Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year - simplywall.st
Aytu BioPharma Inc AY20 Stock Analysis and ForecastMACD Histogram Signals & Superior Trading Ideas - earlytimes.in
How to escape a deep drawdown in Aytu BioPharma Inc.Market Activity Report & High Accuracy Investment Signals - newser.com
Does Aytu BioPharma Inc. qualify in momentum factor screeningTrade Risk Summary & Consistent Return Strategy Ideas - newser.com
Is Aytu BioPharma Inc. stock ready for a breakoutTake Profit & Low Drawdown Investment Ideas - newser.com
Will Aytu BioPharma Inc. stock see insider buyingMarket Growth Review & Consistent Profit Trading Strategies - newser.com
Relative strength of Aytu BioPharma Inc. in sector analysisWeekly Profit Recap & Verified Momentum Stock Watchlist - newser.com
Understanding Aytu BioPharma Inc.’s price movementJuly 2025 Weekly Recap & Stepwise Entry/Exit Trade Alerts - newser.com
Aytu BioPharma outlines $10M EXXUA launch investment and targets breakeven at $17.3M quarterly revenue as ADHD franchise holds strong - MSN
Aytu BioPharma, Inc. (NASDAQ:AYTU) Q1 2026 Earnings Call Transcript - Insider Monkey
Will Aytu BioPharma Inc. (AY20) stock keep high P E multiples2025 Technical Overview & Stock Portfolio Risk Management - newser.com
Earnings call transcript: Aytu BioPharma’s Q1 2025 shows stable stock By Investing.com - Investing.com Australia
Aytu BioPharma Inc (AYTU) Q1 2026 Earnings Call Highlights: Strong ADHD Portfolio Performance ... By GuruFocus - Investing.com Canada
Aytu BioPharma Reports Q1 2026 Earnings and EXXUA Launch Plans - TipRanks
Aytu BioPharma Inc (AYTU) Q1 2026 Earnings Call Highlights: Stro - GuruFocus
Aytu BioPharma Inc (AYTU) Q1 2026 Earnings Call Highlights: Strong ADHD Portfolio Performance ... - Yahoo Finance
Transcript : Aytu BioPharma, Inc., Q1 2026 Earnings Call, Nov 13, 2025 - MarketScreener
Earnings call transcript: Aytu BioPharma's Q1 2025 shows stable stock By Investing.com - Investing.com UK
Earnings call transcript: Aytu BioPharma’s Q1 2025 shows stable stock - Investing.com
Aytu BioPharma Inc. (AYTU) Reports Q1 Loss, Tops Revenue Estimates - sharewise.com
AYTU BIOPHARMA, INC SEC 10-Q Report - TradingView
Aytu BioPharma Reports Fiscal 2026 First Quarter Operational and Financial Results - ACCESS Newswire
Real time social sentiment graph for Aytu BioPharma Inc.Earnings Growth Summary & Weekly High Conviction Ideas - newser.com
Can Aytu BioPharma Inc. (AY20) stock deliver consistent EPS growthProfit Target & AI Powered Market Entry Strategies - newser.com
Insights into Aytu BioPharma's Upcoming Earnings - Benzinga
Aytu BioPharma Inc (AYTU) Q1 2026 Earnings Report Preview: What To Look For - GuruFocus
Finanzdaten der Aytu Biopharma Inc-Aktie (AYTU)
Umsatz
Nettogewinn
Free Cashflow
ENV
Aytu Biopharma Inc-Aktie (AYTU) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Disbrow Joshua R. | Chief Executive Officer |
Jun 09 '25 |
Buy |
1.50 |
66,666 |
99,999 |
153,257 |
| Disbrow Joshua R. | Chief Executive Officer |
Feb 28 '25 |
Buy |
1.30 |
15,000 |
19,500 |
86,591 |
3.00%
0.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):